Joshua Brody, MD discusses the advancing field of bispecific antibodies in third-line relapsed/refractory follicular lymphoma.

Video: https://medicaldigest.org/scientific-contents/interview:bispecific-antibodies-playbook-relapsedrefractory-follicular-lymphoma

Sangeetha Venugopal MD,MS discusses that smoking intensity and duration in patients with myelodysplastic syndromes were tied to distinct genetic mutations, higher mutation burden, and worse survival outcomes, according to a study presented at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:smoking-tied-worsened-disease-progression-myelodysplastic-syndromes

Martin Hutchings, MD, PhD discusses the role of CAR T-Cell therapy and bispecific antibodies in the management of lymphoma at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:addressing-current-questions-and-controversies-regarding-role-car-t-cell-therapy-and-bispecific-antibodies-management-lymphoma

Virginia Kaklamani, MD, DSc discusses estrogen receptor mutations in HR+ advanced breast cancer and generation practice recommendations on mutation screening to guide therapeutic decisions at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:estrogen-receptor-mutations-hr-advanced-breast-cancer-next-generation-practice-recommendations-mutation-screening-guide-therapeutic-decisions

Nan Chen, MD explains patients with early-stage, node-negative, hormone receptor positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:anthracyclines-may-improve-survival-high-risk-breast-cancer-risks-must-be-weighed

Heather McArthur, MD, MPH discusses immunotherapy panel discussion to explore inroads for ER-positive disease, challenges ahead at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:immunotherapy-explore-inroads-er-positive-disease-challenges-ahead

Sherene Loi, MD discusses immune biomarkers in early breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:winding-road-immune-biomarkers-early-breast-cancer

Prof. Sibylle Loibl presented the findings from the phase 3 PADMA clinical trial at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-plus-endocrine-therapy-beats-chemo-hrher2-metastatic-breast-cancer

Shelley Hwang, MD, MPH discusses active monitoring instead of upfront surgery may be a viable option for patients with hormone receptor-positive, HER2-negative, low-risk DCIS, according to results presented at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:comet-trial-finds-active-monitoring-viable-option-some-patients-low-risk-dcis

Otto Metzger, MD presented late-breaking results of the phase 3 PATINA trial showing addition of CDK4/6 inhibitor palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-shows-benefit-hr-her2-metastatic-breast-cancer-patina-trial